Canine Adenovirus Type 2, Strain Manhattan, 12-13-76; Canine Coronavirus, Strain

Verify with FDA CVM →

85 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
85
Total Reports
14
Deaths Reported
1650.0%
Death Rate

Active Ingredients

Canine Adenovirus Type 2, Strain Manhattan, 12-13-76; Canine Coronavirus, Strain

Administration Routes

Subcutaneous

Species Affected

Dog 85

Most Affected Breeds

Retriever - Labrador 12
Chihuahua 9
Terrier - Yorkshire 8
Rottweiler 4
Beagle 3
Pinscher - Miniature 3
Weimaraner 3
Retriever - Golden 3
Terrier - Jack Russell 3
Boxer (German Boxer) 3

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 23
Vomiting 23
Diarrhoea 17
Other abnormal test result NOS 15
Elevated serum alkaline phosphatase (SAP) 10
Fever 9
Anorexia 9
Leucocytosis NOS 9
Death by euthanasia 8
Hypoalbuminaemia 8
Lack of efficacy - NOS 8
Decreased appetite 8

Outcome Breakdown

Ongoing
45 (50.6%)
Recovered/Normal
26 (29.2%)
Euthanized
8 (9.0%)
Died
6 (6.7%)
Outcome Unknown
4 (4.5%)

Data Summary

Metric Value
Total adverse event reports 85
Reports involving death 14
Case-fatality rate (reported events) 1650.0%
Distinct species in reports 1
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Canine Adenovirus Type 2, Strain Manhattan, 12-13-76; Canine Coronavirus, Strain Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 85 adverse event reports referencing Canine Adenovirus Type 2, Strain Manhattan, 12-13-76; Canine Coronavirus, Strain, including 14 reports in which the animal died — a 1650.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Canine Adenovirus Type 2, Strain Manhattan, 12-13-76; Canine Coronavirus, Strain. Reported administration route is Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Canine Adenovirus Type 2, Strain Manhattan, 12-13-76; Canine Coronavirus, Strain reports are Dog (85 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (12), Chihuahua (9), Terrier - Yorkshire (8) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Canine Adenovirus Type 2, Strain Manhattan, 12-13-76; Canine Coronavirus, Strain are Lethargy (see also Central nervous system depression in 'Neurological') (23), Vomiting (23), Diarrhoea (17), Other abnormal test result NOS (15). Of the 89 reports with a coded outcome, Ongoing is the leading category at 50.6%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Canine Adenovirus Type 2, Strain Manhattan, 12-13-76; Canine Coronavirus, Strain.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial